Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Aelius Biotech | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This project will assess the effect of Huel on markers of gastrointestinal inflammation of 30 generally healthy individuals. The aim is to identify any changes in the markers of inflammation status of volunteers in any of the 9 markers to be monitored. Inflammation status will be measured at the start of the study, after one week of their habitual diets and again after four weeks of consuming two ready to drink Huel products per day, one Hot & Savoury Huel (grain-based option only) and the remainder of their calorie intake to be made up of Huel Powder (v3.1).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 4 weeks consumption of Huel ready to eat foods | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Huel | Dietary Supplement | Ready to eat huel foods. Containing 2 ready to drink shakes, one savoury meal pack and meal replacement powder. Consumption amounts were based on energy needs of each person |
| Measure | Description | Time Frame |
|---|---|---|
| C-Reactive protein | baseline and after 4 weeks supplementation | |
| neutrophils | baseline and after 4 weeks supplementation | |
| TNF-alpha | baseline and after 4 weeks supplementation | |
| IL-10 | baseline and after 4 weeks supplementation | |
| IL-6 | baseline and after 4 weeks supplementation |
| Measure | Description | Time Frame |
|---|---|---|
| linoleic acid | baseline and after 4 weeks supplementation | |
| arachidonic acid | baseline and after 4 weeks supplementation | |
| alpha-linoleic acid |
Not provided
Inclusion Criteria:
Generally healthy Aged 18 years and over Non-pregnant, Non-lactating non-smoking
Exclusion Criteria:
Smoker Pregnant Lactating BMI >30 Food allergy Disordered eating Disorder which could impact the study outcomes Medications which could impact the study outcomes
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anthony W Watson, PhD | Newcastle University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of Medical Sciences | Newcastle upon Tyne | Tyne and Wear | NE18ST | United Kingdom |
This is not acceptable due to the ethical approval given
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C120900 | SLC30A9 protein, human |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open label study
Not provided
| baseline and after 4 weeks supplementation |
| eicosapentaenoic acid | baseline and after 4 weeks supplementation |
| Body Mass Index | baseline and after 4 weeks supplementation |
| Body mass | baseline and after 4 weeks supplementation |
| Waist cercumference | baseline and after 4 weeks supplementation |